开搏通配伍葛根素治疗慢性心力衰竭的安全性及疗效观察  

Safety and clinical efficacy of puerarin and caboten in chronic heart failure treatment

作　　者：李德祥[1] 蔡军[1] 张绪权[1] 

机构地区：[1]安徽省霍山县医院,安徽霍山237200

出　　处：《安徽医药》2004年第5期340-341,共2页Anhui Medical and Pharmaceutical Journal

摘　　要：目的　评价开搏通配伍葛根素在慢性心力衰竭 (CHF)患者中应用的安全性及疗效。方法　 2 4例CHF患者 (男 1 4例、女1 0例 )平均年龄 5 6岁 ,心功能Ⅱ—Ⅳ级 ,左室射血分数 (LVEF) 34%。开搏通从小剂量开始 ,只要能耐受 ,尽可能递增到 5 0mg～ 1 0 0mg/d共 2周 ,葛根素 75 0mg加入 5 %葡萄糖 2 5 0ml静脉点滴 ,1次 /d ,共 2周 ,治疗中观察各项相关指标。 结果　治疗后心功能在 6min步行距离较治疗前明显改善。 [2 1 6± 0 70 ]比 [3 1 0± 0 6 8]和 [31 8± 1 70 ]m比 [2 0 5± 1 6 5 ]m ,P <0 0 5 ,心超检查左室舒张末经 (LVEDD)和收缩末经 (LVESD)减少 [(6 1 84± 9 6 0 )mm比 (6 3 4 6± 9 8)mm和 (4 9 4 0± 1 0 4 8)mm比(5 1 1 0± 1 0 88)mm ,P <0 0 5 ,LVEF明显增加 [(2 8 6± 8 6 ) %比 (4 3 6 6± 1 1 0 ) % ,P <0 0 1。心电图示QT离散度明显缩短 [(0 0 96± 0 0 31 ) ]比 (0 0 5 4± 0 0 2 5 )s,P <0 0 1。有少数病人出现咳嗽 ,血K+ 升高 ,乏力等。结论　开搏通配伍葛根素治疗慢性心力衰竭是安全的 ,能明显改善活动耐量 ,改善心功能 ,增加LVEF ,缩短QTd。Aim To evaluate the safety and the clinical efficacy of puerarin and caboten in treatment of chronic congestive heart failure (CHF). Methods Twenty four patients with CHF (male 14. female 10),average age of 56 years old and average EF 34%, underwent cabaton therapy with a dosage of 12 5 mg to 50～100 mg perday if they were tolerated for 2 wks, combined with puerain at a dose of 750 mg once daily for 2 wk. Results After the treatment,NYHA classification and 6 minate walk distance were improved 〔(2 16±0 70) vs (3 10±0 68);(318±170) m vs (201±165) m, P <0 05〕,respectively. LVEDD and LVESD measured by echocardiography reduced 〔(61 8±9 60) mm vs (63 46±9 8) mm;(49 40±10 48) mm vs (51 10±10 88) mm P <0 05〕, respective. Left ventricular eject fraction(LVEF) increased 〔(28 66±8 6)% vs (43 66±11 0)% P <0 01〕. QTD mesasured by electocardiogram reduced 〔(0 096±0 031) vs (0 054±0 025), P <0 01〕. Cough and seram Potassium increased ( P <0 05). Condusion The application of puerarin and cabaton to the treatment of chronic heart failure is saft and effective.

关 键 词：心力衰竭 血管紧张素转换酶抑制药 葛根素 开搏通 

分 类 号：R541.6[医药卫生—心血管疾病] R969[医药卫生—内科学]